论文部分内容阅读
急性冠脉综合征(ACS)涵盖了从不稳定性心绞痛(UA)、非 ST 段抬高的心肌梗死(NSTEMI)到 ST 段抬高的心肌梗死(STEMI)等一系列临床病理生理征候群。近年来,国际上一些大规模随机、双盲试验已证实三羟三甲戊二酰酶 A 还原酶抑制剂(他汀类药物)在有或无冠心病的患者均可以显著减少心血管相关的发生率和死亡率,是冠心病一级和二级预防的有效措施。然而 ACS 患者的发病机制、临床及组织学等特征不同于稳定性冠心病,要求治疗能在较短时间内改善内皮功能障碍等病理现象。ACS 早期应用他汀类药物可
Acute Coronary Syndromes (ACS) covers a range of clinical pathophysiological signs, ranging from unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI) to ST-segment elevation myocardial infarction (STEMI). In recent years, some large-scale randomized, double-blind trials in the world have demonstrated that inhibitors of the NRH-A reductase (statins) can significantly reduce the incidence of cardiovascular events in patients with and without coronary heart disease And mortality, coronary heart disease is a secondary and secondary prevention effective measures. However, the pathogenesis of ACS patients, clinical and histological features are different from the stability of coronary heart disease, requiring treatment in a relatively short period of time to improve endothelial dysfunction and other pathological phenomena. ACS early application of statins can be